Abstract
BackgroundCilostazol overcomes high on-treatment platelet reactivity (HTPR) and reduces adverse cardiovascular (CV) outcomes after percutaneous coronary intervention (PCI). However, the role for triple antiplatelet therapy (TAPT) with cilostazol in addition...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have